SG Americas Securities
VRCA icon

SG Americas Securities’s Verrica Pharmaceuticals VRCA Stock Holding History

SG Americas Securities’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,873
Closed -$13K – 3645
2025
Q1 		$13K Buy
2,873
+971
+51% +$6.28K ﹤0.01% 3403
2024
Q4 		$13K Buy
1,902
+465
+32% +$5.11K ﹤0.01% 3037
2024
Q3 		$21K Buy
+1,437
New +$64.7K ﹤0.01% 3344

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SG Americas Securities's VRCA Position: Q2 2025 in Review

SG Americas Securities sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 2,873 shares — an estimated $13K sold.

SG Americas Securities first reported a position in VRCA in Q3 2024 and held it in 3 quarters. The position peaked at $21K in Q3 2024. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • SG Americas Securities reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 2,873 Verrica Pharmaceuticals shares in Q2 2025, an estimated $13K.
  • SG Americas Securities first reported a position in Verrica Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • SG Americas Securities's Verrica Pharmaceuticals position peaked at $21K in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.